Obesity-drug maker Metsera posts largest gain as IPOs
Jan 31, 2025 · Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their …
OFF
Obesity-drug Maker Metsera Posts Largest Gain As IPOs
2 weeks from now
Jan 31, 2025 · Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their …
morningstar.com
OFF
Obesity-drug Maker Metsera Posts Largest Gain As IPOs Defy …
2 weeks from now
Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market …
msn.com
OFF
Obesity-drug Maker Metsera Posts Largest Gain As IPOs Defy …
2 weeks from now
Jan 31, 2025 · Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their …
morningstar.com
OFF
Metsera’s IPO Raises $275M To Show How Its Obesity Drugs Can …
2 weeks from now
5 days ago · Arch Venture Partners is the largest shareholder with a 23.5% post-IPO stake, according to the filing. Metsera said it will use its cash on hand to finance the Phase 2 test of …
medcitynews.com
OFF
Metsera, Maze Secure Combined $415 Million In IPOs
2 weeks from now
Jan 30, 2025 · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma …
biopharmadive.com
OFF
Weight-loss Drug Developer Metsera Raises $275 Million In US IPO
2 weeks from now
Jan 31, 2025 · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners …
reuters.com
OFF
Obesity-drug Maker Metsera Posts Largest Gain As IPOs
2 weeks from now
Jan 31, 2025 · Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon ... Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on …
marketwatch.com
OFF
FiDi-based Obesity Drug Maker Sees $1.9B IPO
2 weeks from now
Jan 31, 2025 · Largest Private Companies; ... Breadcrumb. Home; Health Pulse; January 31, 2025 01:14 PM. FiDi-based obesity drug maker sees $1.9B IPO. Angel Adegbesan, …
crainsnewyork.com
OFF
Metsera, Inc. Prices Initial Public Offering At $18.00 Per Share ...
2 weeks from now
Jan 31, 2025 · Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments. Quiver AI Summary. Metsera, Inc., a clinical-stage biotechnology …
nasdaq.com
OFF
Weight-loss Drug Developer Metsera Targets Up To $1.78 Billion ...
2 weeks from now
Jan 27, 2025 · Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable …
reuters.com
OFF
Metsera Moves Fast In Crowded Obesity Market With IPO Plans
2 weeks from now
Jan 13, 2025 · Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight …
biospace.com
OFF
Weight-loss Drug Developer Metsera Targets Up To $1.78 Billion ...
2 weeks from now
Jan 27, 2025 · "In 2025, early signs have been encouraging -- Metsera is one of 6 companies that announced IPO plans in January," said William Pickering, senior analyst at Bernstein. "But we …
marketscreener.com
OFF
GLP-1RA Developer Metsera Targets $289m IPO
2 weeks from now
Jan 28, 2025 · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape …
pharmaceutical-technology.com
OFF
Metsera Eyes $289M IPO To Fund Phase 3 Weight Loss Trial
2 weeks from now
Jan 27, 2025 · Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. The New York-based …
fiercebiotech.com
OFF
Obesity Drug Developer Metsera Sets Terms For $275M IPO
2 weeks from now
Jan 27, 2025 · 2d illustrations and photos/iStock via Getty Images. Metsera (), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial …
seekingalpha.com
OFF
Obesity Drug Developer Metsera Files For $100M IPO - MSN
2 weeks from now
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial public offering. While the company didn't specify terms in its SEC filing ...
msn.com
OFF
Obesity Drug Developer Metsera Sets Terms For $275M IPO
2 weeks from now
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said …
msn.com
OFF
Weight-loss Drug Developer Metsera Seeks Up To $1.78 Billion
2 weeks from now
New York City-based Metsera seeks to raise up to $292.2 million by offering 17.19 million shares, priced between $15 and $17 each. The weight-loss drug market, estimated to be worth about …
msn.com
FAQs about Obesity-drug maker Metsera posts largest gain as IPOs Coupon?
Will metsera get a slice of the obesity drug market?
Why did metsera raise $275 million?
What was metsera's IPO price?
Does metsera (MTSR) have a $275M IPO?
Could metsera improve on Novo Nordisk and Eli Lilly's approved obesity treatments?
Will metsera IPO be used to fund a Phase 3 trial?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
